Abivax's Virtual Event: Odefazimod Phase 2b Data and Phase 3 Trials for Ulcerative Colitis

On February 6, 2024, Abivax SA, a clinical-stage biotech firm, will hold a virtual event to discuss the phase 2b clinical results and phase 3 trial design for their drug candidate, obefazimod. The drug is designed to treat patients with moderate to severe ulcerative colitis and operates by enhancing the expression of miR-124, a key regulator of inflammation.

The virtual KOL Investor Event will begin at 2:00 p.m. EST and will include discussions with Marla Dubinsky, MD, and Parambir Dulai, MD, along with Abivax's management team. They will address the current treatment options and unmet needs for ulcerative colitis patients. The event will also delve into the mechanism of action of obefazimod, its phase 2b clinical data, and the design of the upcoming phase 3 trials.

Dr. Dubinsky is a professor at the Icahn School of Medicine and heads the Division of Pediatric GI and Nutrition at Mount Sinai Kravis Children’s Hospital. Dr. Dulai is an Associate Professor at Northwestern University and directs GI Clinical Trials and Precision Medicine. Both are recognized experts in their fields and will provide insights into the challenges and potential of managing ulcerative colitis.

Abivax is a French and US-based company dedicated to creating therapeutics that leverage the body's natural regulatory systems to control the immune response in chronic inflammatory diseases. Their lead candidate, obefazimod, is currently in phase 3 trials for ulcerative colitis treatment.

The event will conclude with a live Q&A session, offering participants an opportunity to engage directly with the experts and the company's management. This event underscores Abivax's commitment to advancing treatments for inflammatory conditions and their dedication to keeping stakeholders informed about their progress and plans.